KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2016 - 2025)

Vertex Pharmaceuticals has reported Total Current Liabilities over the past 17 years, most recently at $3.9 billion for Q4 2025.

  • Quarterly results put Total Current Liabilities at $3.9 billion for Q4 2025, up 8.32% from a year ago — trailing twelve months through Dec 2025 was $3.9 billion (up 8.32% YoY), and the annual figure for FY2025 was $3.9 billion, up 8.32%.
  • Total Current Liabilities for Q4 2025 was $3.9 billion at Vertex Pharmaceuticals, down from $4.5 billion in the prior quarter.
  • Over the last five years, Total Current Liabilities for VRTX hit a ceiling of $4.5 billion in Q3 2025 and a floor of $1.8 billion in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $3.4 billion (2023), compared with a mean of $3.1 billion.
  • Biggest five-year swings in Total Current Liabilities: decreased 4.48% in 2021 and later surged 39.19% in 2022.
  • Vertex Pharmaceuticals' Total Current Liabilities stood at $2.1 billion in 2021, then rose by 28.02% to $2.7 billion in 2022, then rose by 29.37% to $3.5 billion in 2023, then rose by 0.48% to $3.6 billion in 2024, then increased by 8.32% to $3.9 billion in 2025.
  • The last three reported values for Total Current Liabilities were $3.9 billion (Q4 2025), $4.5 billion (Q3 2025), and $4.1 billion (Q2 2025) per Business Quant data.